WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer reaches a global agreement with AbbVie 04 December 2018
Pfizer announces Executive Leadership Team 09 October 2018
Pfizer to award more than $3 million in grants to further breast cancer research 04 October 2018
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy 05 September 2018
Pfizer and Astellas amend clinical research protocols for two phase 3 trials of enzalutamide in patients with hormone-sensitive prostate cancer 29 August 2018
Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy 16 July 2018
Pfizer to organize for future growth 11 July 2018
Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness 14 June 2018
Pfizer to expand venture investing with $600 million commitment to Pfizer Ventures 06 June 2018
The Pfizer Foundation announces $5 million in grants to support women and families 31 May 2018
Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine 22 May 2018
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy 23 April 2018
Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio 03 April 2018
Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis 14 February 2018
Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera® 25 January 2018
FDA approves new Pfizer biosimilar 15 December 2017
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region 01 December 2017
Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma 16 November 2017
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B 08 November 2017
The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries 23 October 2017
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
  • Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
  • Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
  • Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
  • Pfizer to acquire Biohaven Pharmaceuticals

Research & Development

  • "Natural immunity" from omicron is weak and limited, study finds
  • mRNA booster vaccines may be a good investment in developing countries
  • Blocking spike captors to counter COVID
  • Recurring brain tumor growth is halted with new drug
  • Investigational COVID mucosal vaccine protects against disease and transmission
  • Using AI to analyze large amounts of biological data
  • Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, study finds

Conferences & Events

  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference
  • SMi's 6th Annual Highly Potent Active Pharmaceutical Ingredients
  • SMi's 9th Annual Conference Pre-Filled Syringes East Coast

Regulatory Affairs

  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  • FDA approves treatment for wider range of patients with heart failure
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer to acquire Biohaven Pharmaceuticals

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.